Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

660 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Wang ES, Montesinos P, Minden MD, Lee JH, Heuser M, Naoe T, Chou WC, Laribi K, Esteve J, Altman JK, Havelange V, Watson AM, Gambacorti-Passerini C, Patkowska E, Liu S, Wu R, Philipose N, Hill JE, Gill SC, Rich ES, Tiu RV. Wang ES, et al. Among authors: esteve j. Blood. 2022 Oct 27;140(17):1845-1857. doi: 10.1182/blood.2021014586. Blood. 2022. PMID: 35917453 Free PMC article. Clinical Trial.
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.
de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, Esteve J, Bergua JM, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA. de la Serna J, et al. Among authors: esteve j. Blood. 2008 Apr 1;111(7):3395-402. doi: 10.1182/blood-2007-07-100669. Epub 2008 Jan 14. Blood. 2008. PMID: 18195095 Free article. Clinical Trial.
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.
Sanz MA, Montesinos P, Vellenga E, Rayón C, de la Serna J, Parody R, Bergua JM, León A, Negri S, González M, Rivas C, Esteve J, Milone G, González JD, Amutio E, Brunet S, García-Laraña J, Colomer D, Calasanz MJ, Chillón C, Barragán E, Bolufer P, Lowenberg B. Sanz MA, et al. Among authors: esteve j. Blood. 2008 Oct 15;112(8):3130-4. doi: 10.1182/blood-2008-05-159632. Epub 2008 Jul 29. Blood. 2008. PMID: 18664623 Free article.
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.
Montesinos P, Bergua JM, Vellenga E, Rayón C, Parody R, de la Serna J, León A, Esteve J, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA. Montesinos P, et al. Among authors: esteve j. Blood. 2009 Jan 22;113(4):775-83. doi: 10.1182/blood-2008-07-168617. Epub 2008 Oct 22. Blood. 2009. PMID: 18945964 Free article. Clinical Trial.
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, Holowiecka A, Esteve J, Bergua J, González JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Pérez I, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups. Montesinos P, et al. Among authors: esteve j. Blood. 2011 Feb 10;117(6):1799-805. doi: 10.1182/blood-2010-04-277434. Epub 2010 Dec 8. Blood. 2011. PMID: 21148082 Free article. Clinical Trial.
A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia.
Valcárcel D, Montesinos P, Sánchez-Ortega I, Brunet S, Esteve J, Martínez-Cuadrón D, Ribera JM, Tormo M, Bueno J, Duarte R, Llorente A, Torres JP, Guardia R, Sanz MA, Sierra AJ; CETLAM Group. Valcárcel D, et al. Among authors: esteve j. Cancer. 2012 Jan 15;118(2):410-7. doi: 10.1002/cncr.26273. Epub 2011 Jun 29. Cancer. 2012. PMID: 21717435 Free article.
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vellenga E, Holowiecka A, González-Huerta AJ, Fernández P, De la Serna J, Brunet S, De Lisa E, González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM; IC-APL and PETHEMA and HOVON Groups. Sanz MA, et al. Ann Hematol. 2015 Aug;94(8):1347-56. doi: 10.1007/s00277-015-2393-0. Epub 2015 May 15. Ann Hematol. 2015. PMID: 25975975 Clinical Trial.
Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.
Schmid C, Labopin M, Socié G, Daguindau E, Volin L, Huynh A, Bourhis JH, Milpied N, Cornelissen J, Chevallier P, Maertens J, Jindra P, Blaise D, Lenhoff S, Ifrah N, Baron F, Ciceri F, Gorin C, Savani B, Giebel S, Polge E, Esteve J, Nagler A, Mohty M; Acute Leukemia Working Party of the European Group of Blood and Bone Marrow Transplantation. Schmid C, et al. Among authors: esteve j. Blood. 2015 Oct 22;126(17):2062-9. doi: 10.1182/blood-2015-06-651562. Epub 2015 Sep 8. Blood. 2015. PMID: 26351297 Free article.
660 results